古鳌科技(300551.SZ):陈崇军累计减持122万股 减持计划数量过半
格隆汇12月18日丨古鳌科技(300551.SZ)公布,今日,公司收到陈崇军出具的《古鳌科技股份减持比例达到1%暨减持计划数量过半的告知函》,2019年11月20日至2019年12月17日期间,陈崇军通过大宗交易方式累计减持公司股份122万股,占公司总股本比例为1.08%。截至公告披露日,陈崇军减持公司股份数量较其预披露的减持计划数量已过半并达到公司总股本的1%。
此次减持后,陈崇军持有股份4161.25万股,占公司总股本比例36.94%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.